Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Amaia Martinez-Usatorre Clear advanced filters

  • De Palma and colleagues develop a dendritic cell therapy based on dendritic cell progenitors engineered to produce IL-12 and FLT3L and show antigen-agnostic reduction of tumor burden that can be exploited for combination therapy in glioma.

    • Ali Ghasemi
    • Amaia Martinez-Usatorre
    • Michele De Palma
    ResearchOpen Access
    Nature Cancer
    Volume: 5, P: 240-261

  • Tumour-antigen-pulsed mature dendritic cells (DC) have not been as efficient for cancer therapy as hoped to be, due to their sub-optimal antigen-presentation and migration capacities. Here the authors utilise DC progenitors, constitutively expressing IL-12 and an engineered extracellular vesicle-internalizing receptor (EVIR), which give rise to mature conventional type 1 DCs with improved antigen presenting capacities, resulting in improved anti-tumour immunity in a mouse model of melanoma.

    • Ali Ghasemi
    • Amaia Martinez-Usatorre
    • Michele De Palma
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-17

  • Glioblastoma multiforme (GBM) is a lethal form of primary brain cancer. A new study now implicates beta-secretase 1 (BACE1) as a crucial regulator of pro-tumoral IL-6–STAT3 signaling in GBM-associated macrophages. An effective BACE1 inhibitor, clinically developed for Alzheimer’s disease, may offer new hope for GBM treatment.

    • Amaia Martinez-Usatorre
    • Michele De Palma
    News & Views
    Nature Cancer
    Volume: 2, P: 1119-1121

  • Group 2 innate lymphoid cells (ILC2s) modulate inflammatory and allergic responses, but their function in cancer immunity is still unclear. Here the authors show that, in acute promyelocytic leukaemia, tumour-activated ILC2s secrete IL-13 to induce myeloid-derived suppressor cells and support tumour growth.

    • Sara Trabanelli
    • Mathieu F. Chevalier
    • Camilla Jandus
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-14